BUSINESS WIRE: Data from Biogen Idecs Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical …

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

-Scientific Presentations Showcase InnovativeMS Medicines and Experimental Therapies-

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 30.05.2014 --

Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.

Data are being presented during the annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Sixth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS; May 28 May 31 in Dallas, Texas); and the Joint Congress of the European Federation of Neurological Societies (EFNS) and European Neurological Society (ENS; May 31 June 3 in Istanbul, Turkey).

Our research and development efforts over the past 30 years have positioned Biogen Idec at the forefront of MS innovation, and the scope of data we are presenting at CMSC/ACTRIMS and EFNS/ENS underscores our commitment to improving the lives of people living with MS, said Katherine Dawson, M.D., vice president, global medical neurology at Biogen Idec. Beyond discovering new treatments, we are also focused on innovating across the spectrum of MS care, investigating different approaches to advancing disease management.

The data at CMSC/ACTRIMS and EFNS/ENS include results from studies of Biogen Idecs currently marketed products TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab), AVONEX (interferon beta-1a) and FAMPYRA (prolonged-release fampridine tablets) in markets outside of the U.S. as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY (peginterferon beta-1a), daclizumab high-yield process ([DAC HYP], EFNS/ENS presentation only) and Anti-LINGO-1 ([BIIB033], EFNS/ENS presentation only).

Details and Biogen Idec data presentations listings for the 2014 annual CMSC/ACTRIMS Meeting and 2014 Joint Congress of the EFNS and ENS can be found by visiting:

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the worlds oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit http://www.biogenidec.com.

See the rest here:
BUSINESS WIRE: Data from Biogen Idecs Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical ...